Persistence to anti-CGRP monoclonal antibodies and onabotulinumtoxinA among patients with migraine: a retrospective cohort study

Persistence to anti-CGRP monoclonal antibodies and onabotulinumtoxinA among patients with migraine: a retrospective cohort study

Abstract Background To date, real-world evidence on persistence to anti-calcitonin gene-related peptide (anti-CGRP) monoclonal antibodies (mAbs) or onabotulinumtoxinA have excluded eptinezumab. This retrospective cohort study was performed to compare treatment persistency among patients with migrain...

Full description

Bibliographic Details
Main Authors: Larry Charleston, Brian Talon, Christine Sullivan, Carlton Anderson, Steven Kymes, Stephane A. Regnier, Seema Soni-Brahmbhatt, Stephanie J. Nahas
Format: Article
Language:English
Published: BMC 2023-08-01
Series:The Journal of Headache and Pain
Subjects:
Migraine
Persistence
onabotulinumtoxinA
Erenumab
Fremanezumab
Galcanezumab
Online Access:https://doi.org/10.1186/s10194-023-01636-8

Internet

https://doi.org/10.1186/s10194-023-01636-8

Similar Items